Soft Tissue Sarcoma
Conditions
Brief summary
The aim of this study was to developed and validated models to predict therapeutic responses and patients' survivals in patients with soft tissue sarcoma and compared these models with currently available models.
Detailed description
We performed a retrospective-prospective cohort study with the aim of developing and validating comprehensive models to predict treatment responses and survival outcomes in patients with biopsy-proven soft tissue sarcoma. Secondly, we aimed to compare the predictive accuracy with currently available noninvasive model.
Interventions
OTHERPrediction model
We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with soft tissue sarcoma.
Sponsors
West China Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Receiving no treatment before diagnosis * With written informed consent
Exclusion criteria
* Clinical data missing * Without written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment response | At least 1-year follow up | The primary outcome was the evaluation of treatment response to individualized therapy in patients with soft tissue sarcoma. |
| Progression-free survival outcomes | At least 5-year follow up | The endpoint was defined as the occurrence of progression or recurrence, or the last follow-up. Patients were followed from the day of histological diagnosis until the occurrence of progression or recurrence, or last visit. The outcome was evaluated by an experienced oncologist in each center every 3-6 months. At each visit, a medical history, physical examination, and standard laboratory tests were performed. |
| Overall survival outcomes | At least 5-year follow up | The endpoint was defined as the occurrence of death or the last follow-up. Patients were followed from the day of histological diagnosis until the occurrence of progression or recurrence or last visit. The outcome was evaluated by an experienced oncologist in each center every 3-6 months. At each visit, a medical history, physical examination, and standard laboratory tests were performed. |
Countries
China
Contacts
Primary ContactYuhan Yang, MD
Outcome results
None listed